Aberdeen Group
ITCI

Aberdeen Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Aberdeen Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-229,078
Closed -$19.1M – 972
2024
Q4 		$19.1M Sell
229,078
-21,885
-9% -$1.8M 0.04% 379
2024
Q3 		$18.4M Buy
250,963
+17,612
+8% +$1.32M 0.03% 405
2024
Q2 		$16M Buy
233,351
+99,529
+74% +$6.9M 0.03% 425
2024
Q1 		$9.26M Buy
133,822
+75,127
+128% +$5.16M 0.02% 567
2023
Q4 		$4.2M Buy
+58,695
New +$3.38M 0.01% 698

Other funds holding ITCI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Aberdeen Group's ITCI Position: Q1 2025 in Review

Aberdeen Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 229,078 shares — an estimated $19.1M sold.

Aberdeen Group first reported a position in ITCI in Q4 2023 and held it in 5 quarters. The position peaked at $19.1M in Q4 2024. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Aberdeen Group reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Aberdeen Group sold 229,078 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $19.1M.
  • Aberdeen Group first reported a position in Intra-Cellular Therapies Inc. in Q4 2023 and held it in 5 quarters.
  • Aberdeen Group's Intra-Cellular Therapies Inc. position peaked at $19.1M in Q4 2024.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Aberdeen Group's 13F filing for Q1 2025, filed 13 May 2025.